id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ecj-11349	Boccatonda, Andrea; D'Ardes, Damiano; Guagnano, Maria Teresa; Cipollone, Francesco; Santilli, Francesca	Selective serotonin reuptake inhibitors related bleeding risk: case report and review of literature	2023	5	.pdf	application/pdf	4170	224	49	Resting platelets incubated with esc- italopram became most spherical.11 Moreover, an in vitro study showed how medium or high amount of escitalopram can significantly inhibit platelet aggrega- tion induced by ADP and by collagen, together with a reduced expression of glycoprotein (GP)Ib, lysosome-associated membrane glycoprotein 3 (LAMP-3) and GP37 on platelet surface.12-15 Some SSRIs (e.g., fluoxetine, paroxetine or citalopram) may decrease the secondary phase of aggregation in response to ADP, and significantly lower adenosine triphosphate16 and serotonin release in normal platelet rich plasma.13,14 SSRIs can block sero- tonin release from dense granule during platelet aggregation.17 Tseng et al. demonstrated that SSRIs can decrease the amplifi- cation of platelet aggregation secondary to the activation of purinergic receptor P2Y12, thus reducing the activation of the downstream molecules of the ADP signaling pathways.13 Differences between citalopram and other SSRI Citalopram displays a greater effect to inhibit platelet adhesion to both collagen and fibrinogen surfaces than sertraline.6 Moreover, citalopram, but not paroxetine, may significantly decrease P-selectin expression on platelets after ADP activation, thrombin receptor-activating peptides (TRAP) and cross-linked collagen-related peptide (CRP-XL).18 Moreover, DOACs are known to increase the potential risk for upper GI tract bleeding.23 In the work of Wallerstedt et al, the addition of SSRI to war- farin-treated patients was correlated with an increased risk of clin- ically relevant bleeding.24	cache/ecj-11349.pdf	txt/ecj-11349.txt